Pat Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, shared a post by UroToday.com on X, adding:
“Shortage of BCG has been a problem for a decade now. We solved this with a supercharged BCG ImmunityBio. Together with the Bioshield it drives memory T cells in patients with bladder cancer.”
Quoting UroToday.com‘s post:
“Recombinant BCG Access Program Addresses US Bladder Cancer Shortage – Neal Shore, MD, FACS, CURC and Ashish M. Kamat discuss recombinant BCG, now available via FDA-expanded access. Amid chronic shortages, this “supercharged” version offers scalable supply, flexible use (with or without N-803), and early efficacy, restoring hope for NMIBC care. Watch Now.”
Proceed to the video attached to the post.
You Can Also Read: Bladder Cancer: Symptoms ,Causes, Stages, Diagnosis and Treatment
